

**Table S1.** Secondary attack rates and adjusted relative risks by sex, age and vaccination status of index cases in the South Korea

Characteristic	Total				
	Index cases	Household transmission			
	Total (%)	Total (%)	Confirmed, SAR (%)	Crude RR (95% CI)	aRR (95% CI) <sup>a)</sup>
Total	4,450 (100)	10,382 (100)	2,877 (27.7)	-	-
Sex					
Male	2,142 (48.1)	5,157 (49.7)	1,425 (27.6)	Reference	Reference
Female	2,308 (51.9)	5,225 (50.3)	1,452 (27.8)	1.01 (0.93–1.10)	0.99 (0.90–1.08)
Age (y)					
≤ 19	1,812 (40.7)	4,800 (46.2)	1,286 (26.8)	0.78 (0.70–0.86)	0.62 (0.54–0.70)
20–29	577 (13.0)	1,171 (11.3)	266 (22.7)	0.63 (0.53–0.73)	0.77 (0.65–0.92)
30–49	1,287 (28.9)	2,903 (28.0)	928 (32.0)	Reference	Reference
50–74	704 (15.8)	1,393 (13.4)	353 (25.3)	0.72 (0.63–0.83)	0.92 (0.79–1.08)
≥ 75	70 (1.6)	115 (1.1)	44 (38.3)	1.32 (0.90–1.94)	1.87 (1.23–2.84)
Vaccination status					
Unvaccinated	2,412 (54.2)	5,948 (57.3)	1,833 (30.8)	Reference	Reference
1 Dose					
1 mRNA	211 (4.7)	477 (4.6)	119 (24.9)	0.75 (0.60–0.93)	0.68 (0.54–0.87)
2 Dose					
mRNA (≤ 90 d)	917 (20.6)	2,030 (19.6)	450 (22.2)	0.64 (0.57–0.72)	0.56 (0.48–0.65)
mRNA (> 90 d)	823 (18.5)	1,758 (16.9)	452 (25.7)	0.78 (0.69–0.88)	0.68 (0.58–0.79)
3 Dose					
3 mRNA	87 (2.0)	169 (1.6)	23 (13.6)	0.35 (0.23–0.55)	0.28 (0.18–0.46)

SAR, secondary attack rate; RR, relative risk; aRR, adjusted RR; CI, confidence interval.

<sup>a)</sup>Adjusted by variant, sex, age, vaccine status, date of diagnosis date of index cases and household contacts.